[{"id":"0e73abb6-f88d-4f24-b05c-ace00579c534","acronym":"","url":"https://clinicaltrials.gov/study/NCT00693342","created_at":"2021-01-18T02:35:28.406Z","updated_at":"2024-07-02T16:36:49.661Z","phase":"Phase 3","brief_title":"Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission","source_id_and_acronym":"NCT00693342","lead_sponsor":"Gynecologic Oncology Group","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e polyvalent vaccine-KLH conjugate"],"overall_status":"Withdrawn","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-02-24"},{"id":"f157b179-f000-4f08-9439-f1b1fb4a51f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT01223235","created_at":"2021-01-18T04:54:57.916Z","updated_at":"2024-07-02T16:37:10.111Z","phase":"","brief_title":"Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab","source_id_and_acronym":"NCT01223235","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ALK • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["ALK • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • polyvalent vaccine-KLH conjugate"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 09/01/2017","study_completion_date":" 09/01/2017","last_update_posted":"2018-06-12"}]